<DOC>
	<DOC>NCT01863745</DOC>
	<brief_summary>The purpose of this study is to collect and assess long-term safety of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology CD&amp;MA study and are benefiting from the treatment as judged by the investigator.</brief_summary>
	<brief_title>Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Patient is currently enrolled in a Novartissponsored, Oncology CD&amp;MA study receiving nilotinib and benefiting from the treatment with nilotinib, as determined by the investigator. Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, noncompliance to study procedures, withdrawal of consent or any other reason. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ggastrointestinal stromal tumors</keyword>
	<keyword>gastrointestinal,</keyword>
	<keyword>stromal,</keyword>
	<keyword>tumors,</keyword>
	<keyword>GIST,</keyword>
	<keyword>AMN107,</keyword>
	<keyword>nilotinib</keyword>
</DOC>